The landscape of artificial intelligence (AI) is evolving rapidly, and one of its most exciting domains is large language models (LLMs) powering AI chatbots. These models hold immense potential to transform how we interact with technology, offering personalised assistance in...
Welcome from the Honorary Secretary I am thrilled to extend a warm welcome to each and every one of you as we gear up for what promises to be an enriching and enlightening conference experience. On behalf of Mo Belal,...
I suspect that if Dominic Corrigan (famous for the metaphorical escape route afforded to busy clinicians) was a urologist he would most certainly have had a copy of the The 5-Minute Urology Consult and would have then subsequently been famous...
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the second history column I wrote for Urology News, way back in...
The concluding statement of this short review states, “the study of the urinary microbiome and its impact on urological disease, including IC/BPS, is in its infancy.” A lot has been said on this subject in recent years, but this, in...
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...
Socioeconomic status as an established determinant of health and associated injustices is well recognised. Confronting these injustices and creating a fairer healthcare system is an ongoing challenge for many governments. In Scotland, the devolved government has created the Scottish Index...
In this series of articles I am going to show you some of the exhibits contained in the BAUS Virtual museum of the History of Urology which is part of the BAUS website (www.baus.org.uk). In the last article I told...
In Western countries, we are spoilt for choice in almost every aspect of our lives, but does that reflect also in healthcare? While we have taken some big strides towards shared decision-making with our patients, the age-old physician dominance remains...
Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...
Touijer and colleagues present extended follow-up results from a large randomised trial comparing limited pelvic lymph node dissection (l-PLND) and extended PLND (e-PLND) in prostate cancer patients undergoing radical prostatectomy. The study aimed to assess whether e-PLND, which includes external...
Subjects in this paper were part of the Reduction by Dutasteride of PCa Events (REDUCE) study, a clinical trial enrolling men who had undergone a single negative prostate biopsy within six months of enrollment and subjecting them to a repeat...